account adjust acquisition-rel cost certain
signific item
revenu ep ahead estim top bottom line guidanc increas
alreadi reflect forecast
ep ahead estim consensu
ep guidanc rais narrow prior fx impact
estim slightli posit vs prior last publish ep estim
sale estim
consensu product beat estim includ gardasil singulair
zepati vytorin remicad combin forecast
isentress line estim product forecast includ keytruda
simponi zetia januvia cubicin combin
forecast anim health sale estim sale guidanc
rais narrow prior includ fx impact
unchang last publish revenu estim
gpm estim
estim sg estim net non-
oper incom forecast tax rate
estim ad ep share count
forecast
event expect includ truda data sclc bladder tnbc
 approv pdufa sclc pdufa
lynparza w/azn eu/jp/cn approv ovarian posit chmp apr
file brcam pancreat cancer ph ii data endometri pain
pneumococc vaccin ph ii data healthi infant investor day june nyc
complet list event shown follow page
pleas see page report import disclosur
merck competit posit line lung cancer clear posit merck face
uncertainti includ januvia outlook competit market competit pressur
isentress zostavax thin pipelin believ risk balanc opportun
therefor remain market perform stock
uptak keytruda nsclc
keytruda data readout variou tumor
keytruda approv
lynparza eu approv ovarian
oper margin improv
expect
new product unabl off-set januvia
zetia cubicin patent expir
competit pressur zostavax
merck global health care compani includ prescript medicin vaccin
biolog therapi anim health strong product presenc oncolog
cardiovascular anti-infect anti-inflammatori diabet area among other
anim health divis focus mainli feed anim
cowen compani
cowen compani compani data
cowen compani
cowen compani
cowen compani
m-m-r ii cowen
cowen compani
time frameev data sclc w/chemoph ii data nmibc bladderph data bladderph data tnbcph data neoadjuvant/adjuv tnbcph data tnbcph data msi-h stage iv crcph ii data cscclynparza w/azn full ph data polo brcam pancreat cancer met primari endpt ascoph data ovarian mainten regardless brca statu w/avastin data profound ii data ii data hivrelebactemph data w/imipenem cilastatin imipenem non-suscept bacteri infectionssteglatrophas verti cv cv outcom pneumoccoc vaccin first ph ii data healthi infant regulatorydelstrigo pifeltr label updat use switch patient pdufa vaccin file roll submiss keytrudau approv pdufa approv sclc pdufa file esophag cancer w/azn regulatori file pancreat cancereu/jp/cn approv brcam ovarian cancer posit chmp apr approv fdc w/imipenem cilastatin cuti ciai pdufa approv vabp/habp dayjun nyc cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock merck novarti adr roch hold ltd adr secur
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
cowen compani llc act financi advisor inc connect acquisit roch hold ag announc februari
author report member author household long posit equiti secur merck
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
